Sodium Cromoglycate Alone and in Combination With Montelukast on the Airway Response to Mannitol in Asthmatic Subjects
- 1 May 2010
- journal article
- research article
- Published by Informa UK Limited in Journal of Asthma
- Vol. 47 (4), 429-433
- https://doi.org/10.3109/02770900903584043
Abstract
Background. Mannitol, inhaled as a dry powder, is used for bronchial provocation to identify bronchial hyperresponsiveness. Bronchoconstriction is associated with an increase in urinary excretion of the metabolites of prostaglandin D2 and leukotriene E4. Sodium cromoglycate provides about 60% protection against the fall in forced expiratory volume in one second (FEV1) provoked by inhaled mannitol and appears to do so by inhibiting the release of prostaglandin D2 but not leukotriene E4.The leukotriene receptor antagonist montelukast does not alter sensitivity to mannitol, as measured by the provoking dose to cause a 15% fall in FEV1 to mannitol, but it significantly enhances recovery from the bronchoconstriction provoked by mannitol. Objective. The authors proposed that the combination of these two drugs would be superior to sodium cromoglycate alone and result in greater protection from the bronchoconstriction provoked by mannitol. Methods. The % fall in FEV1 from baseline and the area under the 30-min FEV1 time curve and time to recover to 95% baseline FEV1 were used to express protection from 40 mg sodium cromoglycate alone, and in combination with 10 mg montelukast, in subjects with asthma. Mannitol was inhaled in the dose that caused a 20% fall in FEV1 on the screening day. The prechallenge medications were randomised on the 3 treatment days and were (1) placebo sodium cromoglycate and placebo montelukast; (2) sodium cromoglycate and placebo montelukast; and (3) sodium cromoglycate and montelukast. Results. The protection by sodium cromoglycate alone on the % fall in FEV1 was 64.4% ± 21.0% versus 65.8% ± 62.8% (p = NS) on the combination. The protection on the area under the 30-min FEV1 time curve for sodium cromoglycate was 81.8% ± 14.0% (p <.04) and 89.3% ± 9.8% for the combination (p <.001) compared with placebo. Recovery to 95% baseline FEV1 by 5/10 min occurred in 58%/66% of subjects on sodium cromoglycate and 66%/83% on the combination compared with 0%/0% on placebo. Conclusion. The addition of montelukast to sodium cromoglycate provided only a small additional benefit against the airway response to mannitol.Keywords
This publication has 22 references indexed in Scilit:
- Mannitol and exercise challenge tests in asthmatic childrenPediatric Pulmonology, 2009
- Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthmaJournal of Allergy and Clinical Immunology, 2007
- Release of prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast cellsAllergy, 2006
- Monitoring mast cell activation by prostaglandin D2 in vivoThorax, 2004
- Evidence of mast cell activation and leukotriene release after mannitol inhalationEuropean Respiratory Journal, 2003
- Effects of mediator antagonism on mannitol and adenosine monophosphate challengesClinical and Experimental Allergy, 2003
- The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: A role for the airway epithelium?Journal of Allergy and Clinical Immunology, 1996
- Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma.Thorax, 1985
- Disodium CromoglycateInternational Archives of Allergy and Immunology, 1970
- A DOUBLE-BLIND TRIAL OF DISODIUM CROMOGLYCATE IN THE TREATMENT OF ALLERGIC BRONCHIAL ASTHMAThe Lancet, 1967